Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma Topic Center

Featured Article

News
Early, Late DLBCL Relapse Linked With Distinct Evolutionary Dynamics
08/17/2023
Jolynn Tumolo
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have...
08/17/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Jolynn Tumolo
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Study Finds Low Rate of CAR T-cell Therapy in Older Adults With DLBCL
07/27/2023
Jolynn Tumolo
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was...
07/27/2023
First Report Managed Care
News
CNS Prophylaxis Shows Limited Effectiveness in Preventing CNS Relapse in DLBCL
07/21/2023
Jolynn Tumolo
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness,...
07/21/2023
First Report Managed Care
News
Prognosis Worse for Patients With DLBCL and Mental Health Disorders
07/20/2023
Julie Gould
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse...
07/20/2023
First Report Managed Care
News
Epcoritamab Shows Durable Response in Relapsed/Refractory Large B-Cell Lymphoma
07/14/2023
Jolynn Tumolo
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response...
07/14/2023
First Report Managed Care
News
Biosimilar Rituximab Compared to Originator Rituximab for Treatment of Patients With DLBCL
05/12/2023

Jordan Kadish

Jordan Kadish
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a...
05/12/2023
Oncology
From Oncology
Elizabeth Brem University of California Irvine
Videos
Analyzing Patient Selection and the Utility of CNS Prophylaxis for Patients With DLBCL
04/20/2023
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great...
04/20/2023
Oncology
From Oncology
Jennifer Amengual, MD, Columbia University
Videos
Choosing Treatment Options for Patients With R/R DLBCL Ineligible for CAR T-Cell Therapy
04/18/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates &...
04/18/2023
Oncology
From Oncology
News
Anti-CD19 Monoclonal Antibodies for Treating Patients With R/R DLBCL
05/20/2022
Maria Asimopoulos
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed...
05/20/2022
First Report Managed Care
News
Loncastuximab Tesirine Efficacious, Safe for Patients With R/R DLBCL
05/13/2022
Jolynn Tumolo
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the...
05/13/2022
First Report Managed Care

Newsfeed

News
Early, Late DLBCL Relapse Linked With Distinct Evolutionary Dynamics
08/17/2023
Jolynn Tumolo
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have...
08/17/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Jolynn Tumolo
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Study Finds Low Rate of CAR T-cell Therapy in Older Adults With DLBCL
07/27/2023
Jolynn Tumolo
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was...
07/27/2023
First Report Managed Care
News
CNS Prophylaxis Shows Limited Effectiveness in Preventing CNS Relapse in DLBCL
07/21/2023
Jolynn Tumolo
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness,...
07/21/2023
First Report Managed Care
News
Prognosis Worse for Patients With DLBCL and Mental Health Disorders
07/20/2023
Julie Gould
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse...
07/20/2023
First Report Managed Care
News
Epcoritamab Shows Durable Response in Relapsed/Refractory Large B-Cell Lymphoma
07/14/2023
Jolynn Tumolo
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response...
07/14/2023
First Report Managed Care
News
Biosimilar Rituximab Compared to Originator Rituximab for Treatment of Patients With DLBCL
05/12/2023

Jordan Kadish

Jordan Kadish
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a...
05/12/2023
Oncology
News
Anti-CD19 Monoclonal Antibodies for Treating Patients With R/R DLBCL
05/20/2022
Maria Asimopoulos
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed...
05/20/2022
First Report Managed Care
News
Loncastuximab Tesirine Efficacious, Safe for Patients With R/R DLBCL
05/13/2022
Jolynn Tumolo
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the...
05/13/2022
First Report Managed Care
News
HRQoL Maintained or Improved With Treatment for Patients With R/R DLBCL
04/25/2022
Jolynn Tumolo
An antibody-drug conjugate already shown to have antitumor activity and manageable toxicity also improved health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma, according to new findings. 
An antibody-drug conjugate already shown to have antitumor activity and manageable toxicity also improved health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma, according to new findings. 
An antibody-drug conjugate...
04/25/2022
First Report Managed Care
News
Keratoconus Appears to be Associated With Demodex Mites
05/16/2024
Jolynn Tumolo
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
Keratoconus, an eye disorder...
05/16/2024
First Report Managed Care
News
Hospital Costs May Be Higher for Patients With Private Insurance
05/14/2024
Hannah Musick
A recent research report reveals that individuals with private health insurance pay 254% more for hospital procedures than Medicare rates, leading to potentially increased costs for millions of Americans.
A recent research report reveals that individuals with private health insurance pay 254% more for hospital procedures than Medicare rates, leading to potentially increased costs for millions of Americans.
A recent research report reveals...
05/14/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
Demodex Infestation Found in 9 of 10 Eye Clinic Patients Using 2-Minute Technique
05/09/2024
Jolynn Tumolo
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the...
05/09/2024
First Report Managed Care
News
Debate Emerges Over FDA's Plan to Regulate Laboratory Medical Tests
05/03/2024
Hannah Musick
The FDA's new regulations on laboratory-developed tests have sparked debate over access to innovative tests and patient care in the medical field, with opponents arguing that increased oversight could hinder the development of crucial new...
The FDA's new regulations on laboratory-developed tests have sparked debate over access to innovative tests and patient care in the medical field, with opponents arguing that increased oversight could hinder the development of crucial new...
The FDA's new regulations on...
05/03/2024
First Report Managed Care
News
Analysis Shows Proposed CMS ‘Best Price’ Rule May Increase Rebate Liability, Impacting Medicaid
04/26/2024
Dean Celia
A proposed rule from Centers for Medicare & Medicaid Services (CMS), “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program,” has been in the spotlight recently. Major health...
A proposed rule from Centers for Medicare & Medicaid Services (CMS), “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program,” has been in the spotlight recently. Major health...
A proposed rule from Centers for...
04/26/2024
First Report Managed Care
News
Rebalancing Coagulation Pathways and Human Factor 9 Gene Knock-In Strategy Identified for Hemophilia B
04/25/2024

Grace Taylor

Grace Taylor
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular...
04/25/2024
First Report Managed Care
News
Neurologist Recognized for Pioneering MS Research and Treatment Strategies
04/24/2024
Hannah Musick
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the...
04/24/2024
First Report Managed Care
News
Chicago Sky Blue May be Considered as a Diagnostic Stain for Visualizing Demodex in Patients With Demodex Blepharitis
04/24/2024
Lisa Kuhns, PhD
Chicago sky blue is a promising stain that can identify and quantify the number of Demodex mites in patients with Demodex blepharitis, according to a study published in PeerJ.
Chicago sky blue is a promising stain that can identify and quantify the number of Demodex mites in patients with Demodex blepharitis, according to a study published in PeerJ.
Chicago sky blue is a promising...
04/24/2024
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care

Advertisement

Advertisement

FRMC Volume 21, Issue 1

Current Issue

March 2024
Volume 21
Issue 1
Current Issue
Issue Archive

Advertisement

What's Trending?

News
CMS Issues Rules on Loss Ratios for Medicare Plans
02/19/2013
02/19/2013
First Report Managed Care
Cover Story
Navigating Work With PBMs: Negotiations, Misalignments, and Drug Costs
12/07/2023
Mary Beth Nierengarten
Ignoring the appropriate use of drugs is equally harmful when negotiating with PBMs, as it can and does result in the wrong drugs getting on a formulary with the obvious downstream effect on patient care, costs, and outcomes.
Ignoring the appropriate use of drugs is equally harmful when negotiating with PBMs, as it can and does result in the wrong drugs getting on a formulary with the obvious downstream effect on patient care, costs, and outcomes.
Ignoring the appropriate use of...
12/07/2023
First Report Managed Care
News
Doctors limit new Medicare patients
06/21/2010
06/21/2010
First Report Managed Care
News
New Heart Drug Guidelines Efficient and Cost Effective
07/15/2015
New guidelines for prescribing cholesterol-lowering medications are efficient and cost-effective, according to two new studies.
New guidelines for prescribing cholesterol-lowering medications are efficient and cost-effective, according to two new studies.
New guidelines for prescribing...
07/15/2015
First Report Managed Care
News
Demodex Infestation Found in 9 of 10 Eye Clinic Patients Using 2-Minute Technique
05/09/2024
Jolynn Tumolo
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the...
05/09/2024
First Report Managed Care

Video Insights

Elizabeth Brem University of California Irvine
Videos
Analyzing Patient Selection and the Utility of CNS Prophylaxis for Patients With DLBCL
04/20/2023
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great...
04/20/2023
Oncology
Jennifer Amengual, MD, Columbia University
Videos
Choosing Treatment Options for Patients With R/R DLBCL Ineligible for CAR T-Cell Therapy
04/18/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates &...
04/18/2023
Oncology
Tejaswi Kompala
Videos
Personalizing Weight Loss Management With GLP-1 Agonists
04/05/2024

Featuring Tejaswi Kompala, MD, head of cardiometabolic clinical strategy, Teladoc 

Featuring Tejaswi Kompala, MD, head o...
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Delve into the rising demand for...
04/05/2024
First Report Managed Care
Zaubler Headshot
Videos
Integrating Behavioral Health Services to Reduce ED Visits: Substance Use Disorder and Social Determinants of Health
03/27/2024

Featuring Tom Zaubler, MD, MPH, CMO at NeuroFlow

Featuring Tom Zaubler, MD, MPH, CMO a...
Join us for the continuation of an engaging two-part series showcasing an expert dedicated to reducing emergency department visits through the integration of behavioral health practices. Dr Zaubler will share invaluable insights into...
Join us for the continuation of an engaging two-part series showcasing an expert dedicated to reducing emergency department visits through the integration of behavioral health practices. Dr Zaubler will share invaluable insights into...
Join us for the continuation of...
03/27/2024
First Report Managed Care
Zaubler Headshot
Videos
Integrating Behavioral Health Services to Reduce ED Visits: Suicide Prevention and Preemptive Primary Care
03/25/2024

Featuring Tom Zaubler, MD, MPH, CMO at NeuroFlow

Featuring Tom Zaubler, MD, MPH, CMO a...
Come join us for the first installment of a captivating two-part series featuring an expert committed to minimizing emergency department visits through the implementation of behavioral health integrations. Dr Zaubler will offer valuable...
Come join us for the first installment of a captivating two-part series featuring an expert committed to minimizing emergency department visits through the implementation of behavioral health integrations. Dr Zaubler will offer valuable...
Come join us for the first...
03/25/2024
First Report Managed Care
Yash Prajapati
Videos
Navigating the Evolution of Digital Solutions in Health Care
02/27/2024

Featuring Yash Prajapati, consultant at ZS Associates 

Featuring Yash Prajapati, consultant ...
Join us in exploring the challenges and opportunities in the development, approval, and integration of digital therapeutic solutions with ZS Associates consultant Yash Prajapati.
Join us in exploring the challenges and opportunities in the development, approval, and integration of digital therapeutic solutions with ZS Associates consultant Yash Prajapati.
Join us in exploring the...
02/27/2024
First Report Managed Care
Mansur Shomali
Videos
Advancements and Challenges in Diabetes Management
02/27/2024

Featuring Mansur Shomali, MD, chief medical officer at Welldoc, endocrinologist at MedStar Health 

Featuring Mansur Shomali, MD, chief m...
Learn about the state of digital therapeutics for disease management such as diabetes care in terms of cost, outcomes, integration, and more with Dr Mansur Shomali, CMO at Welldoc.
Learn about the state of digital therapeutics for disease management such as diabetes care in terms of cost, outcomes, integration, and more with Dr Mansur Shomali, CMO at Welldoc.
Learn about the state of digital...
02/27/2024
First Report Managed Care
kevin cowart md
Videos
Costs and Benefits: How a New Cholesterol-Lowering Drug Compares to Others
10/24/2023

Featuring Kevin Cowart, PharmD, MPH, BCACP, CDCES

Featuring Kevin Cowart, PharmD, MPH, ...
Dr Kevin Cowart, assistant professor at the University of South Florida College of Pharmacy, discusses inclisiran, a new non-statin treatment for high cholesterol.
Dr Kevin Cowart, assistant professor at the University of South Florida College of Pharmacy, discusses inclisiran, a new non-statin treatment for high cholesterol.
Dr Kevin Cowart, assistant...
10/24/2023
First Report Managed Care
John Hennessy Headshot
Videos
Biosimilars, Explained
10/24/2023

Featuring John Hennessey, MBA

Featuring John Hennessey, MBA
In this video, John Hennessey, MBA, Valuate Health Consultancy, explains biosimilars in relation to cancer care: what they are, why they matter, and how they have and haven’t lived up to their promise.
In this video, John Hennessey, MBA, Valuate Health Consultancy, explains biosimilars in relation to cancer care: what they are, why they matter, and how they have and haven’t lived up to their promise.
In this video, John Hennessey,...
10/24/2023
First Report Managed Care
Videos
AVAHO 2023: Andrew Brunner, MD, Discusses Updates in MDS
10/20/2023

Featuring Andrew Brunner, MD

Featuring Andrew Brunner, MD
In this video, Dr Brunner reviews his recent discussion he held at the 2023 AVAHO Annual Meeting, and provides treatment updates in the treatment of MDS.
In this video, Dr Brunner reviews his recent discussion he held at the 2023 AVAHO Annual Meeting, and provides treatment updates in the treatment of MDS.
In this video, Dr Brunner...
10/20/2023
First Report Managed Care
Dr Kesty Headshot
Videos
A Dermatologist's Perspective on Demodex Blepharitis: Causes, Symptoms, and Treatment Options
10/19/2023

Featuring Katarina Kesty, MD, MBA, FAAD, Dermatologist and Medical Director at St. Petersburg Skin and Laser

Featuring Katarina Kesty, MD, MBA, FA...
Katarina Kesty, MD, MBA, FAAD, Dermatologist and Medical Director at St. Petersburg Skin and Laser, weighs in on Demodex blepharitis, a condition characterized by inflammation of the eyelid margin caused by an overpopulation of Demodex mites,...
Katarina Kesty, MD, MBA, FAAD, Dermatologist and Medical Director at St. Petersburg Skin and Laser, weighs in on Demodex blepharitis, a condition characterized by inflammation of the eyelid margin caused by an overpopulation of Demodex mites,...
Katarina Kesty, MD, MBA, FAAD,...
10/19/2023
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement